Association Between Abnormal Cardiac Biomarkers And Mortality In Covid-19 Patients

Juan E. Gomez-Mesa,Manuela Escalante,Diego L. Quintero,Daniel Lopez,Hoover Leon,Eduardo Perna,Alexander Romero,Mendoza Ivan,Fernando Wyss,Jose L. Barisani,Mario Speranza,Walter Alarco

DOI: https://doi.org/10.1016/j.cardfail.2023.10.358

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction The coronavirus disease (COVID-19) has been associated with myocardial injury or cardiac involvement. Current evidence indicates that elevated cardiac biomarkers are associated with worse outcomes. Objective Evaluate and compare which cardiac biomarker have the greatest clinical relevance in patients with COVID-19. Methods CARDIOCOVID 19-20 is an observational, ambispective, multicenter registry that included hospitalized patients with confirmed COVID-19 in 44 hospitals in 14 Latin American and Caribbean countries. We included patients who had troponin, natriuretic peptide, and D-dimer tests performed during hospitalization and divided them into 4 groups, those who had one, two or three abnormal or positive biomarkers, and those who had all negative. Results 476 patients had troponin, D-dimer, and natriuretic peptide tests performed during hospitalization and were classified as follows: 139 patients had 1 abnormal test (1AT), 190 had 2 abnormal tests (2AT), 118 had 3 abnormal tests (3AT) and 29 with all 3 tests normal (0AT). Median age was 64 years, and older patients were those that presented 3AT (69 years, p<0.001). In all groups, male was the predominant gender (Table 1A). Decompensated heart failure occurred in 35.6% of patients with 3AT, 18.4% of patients with 2AT, and 5.0% of patients with 1AT, while no patient with 0AT presented this complication (p<0.001). Invasive mechanical ventilation was required in more than 50% and ICU admission was required in more than 70% in those who presented at least one AT. Regarding mortality, the greater the number of elevated biomarkers, the greater the mortality, being 50.0%, 31.1%, and 18.0% in patients with 3AT, 2AT, and 1AT groups, respectively (p<0.001). We analyzed the group with 2AT and found that the overall mortality was 31.0% (59). Mortality of those who had positive troponin and natriuretic peptide was 43.2%, positive troponin and D-dimer was 44.0%, and positive natriuretic peptide and D-dimer was 24.0%. Of the 59 patients who died, 29 patients had positive natriuretic peptide and D-dimer (49.2%) and 19 patients the combination troponin and natriuretic peptide (32.2%). This means that patients who had positive troponin and natriuretic peptide, and positive troponin and D-dimer were 1.4 and 1.5 times more likely to die compared to those who had positive natriuretic peptide and D-dimer, respectively (Table 1B, 1C). Conclusion In COVID-19 patients, the higher the number of positive biomarkers (troponin, natriuretic peptide and / or D-dimer), the higher the prevalence of cardiovascular complications during hospitalization, and the higher the cardiovascular mortality.

cardiac & cardiovascular systems